Helping to realize data-driven, personalized care that treats patients based on their unique genomic characteristics across therapeutic areas.
We are rapidly moving towards individualized treatments and disease interventions that will change how we care for people around the world.
For years, patients diagnosed with a disease often received the same treatment. And for some people, that treatment worked. However, for others, it did not at all work – or only marginally or with serious side effects. This meant that, on average, only 50% of patients benefited from their treatment. With the mapping of the genome in combination with new, analytical scientific and technological advances, we can now develop personalized treatments for individuals or patient populations.
Huge advances in areas like cell and gene therapy, specifically in oncology and rare diseases are changing the treatment landscape. We conducted research to understand the key trends in precision oncology and how leaders are responding.
It’s our privilege to be working with the most progressive life sciences companies to bring precision medicine to people around the world.
We bring capabilities from early research through full commercialization in combination with deep technology and digital expertise to help our clients deliver personalized healthcare to their patients.
Leveraging our data science expertise: accelerate R&D, enable clinically relevant biomarkers, action patient care analytics along their lifespan.
Shaping and designing industry-leading patient and healthcare professional experiences and services with our business service design arm Fjord.
Aggregating, analyzing and actioning patient data and insight from across their healthcare and everyday experience using architectures and platforms, including INTIENT.
Bringing our deep precision medicine expertise to help clients design and build drug development for shifting manufacturing and commercial operations.
Precision medicine holds great promise for reshaping the way we treat cancer, yet research shows that there are hurdles before realizing its full potential.